| Popis: |
Objective: To observe the effect on Immune function and pulmonary function of montelukast sodium combined with azithromycin in children with mycoplasma pneumonia. Methods: A total of 100 cases of MPP children according to the inclusion sequence were divided into observation group and control group, 50 cases in each. The control group was given azithromycin, and the observation group was given montelukast sodium based on the control group. After 2 weeks, to observe the changes of immune function (IgG, IgA, IgM and CD4+, CD8+, CD4+/CD8+) and pulmonary function (FEV1, FVC, PEV and MEF50) between the two groups. Results: (1) After treatment, IgG, IgM of the two groups decreased and IgA increased obviously; CD4+, CD4+/CD8+ of the two groups increased and CD8+ decreased obviously; observation group after treatment, levels of IgM, IgA, CD8+ were (1.10+0.39) g/L, (1.14+0.38) g/L, (24.23+4.53)% , respectively, which was significantly lower than that of the control group, levels of IgG, CD4+ and CD4+/CD8+ were (9.73±2.72) g/L, (35.54±8.30)% and (1.43±0.40)% ,respectively, which was significantly higher than that of the control group after treatment. At the same time, the difference has statistical significance. (2) After treatment, FEV1, FVC, PEV and MEF50 of the two groups increased obviously, observation group after treatment, FEV1, FVC, PEV and BPT were (2.29±0.53) L, (78.52±8.35)%, (4.27±0.67) L/S, (71.43±9.03) L/S, respectively, which was significantly higher than that of the control group, the difference was statistically significant. Conclusion: combination of montelukast sodium have greater regulation of immune function disorder and more conducive to improving lung function when Azithromycin treatment for child MPP. |
